CSS
NPCE icon

Cubist Systematic Strategies’s Neuropace NPCE Stock Holding History

Cubist Systematic Strategies’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-95,618
Closed -$1.07M – 3369
2025
Q2 		$1.07M Buy
+95,618
New +$1.2M ﹤0.01% 1913
2025
Q1 		– Sell
-9,981
Closed -$112K – 3304
2024
Q4 		$112K Buy
+9,981
New +$86.8K ﹤0.01% 2692
2024
Q3 		– Sell
-11,519
Closed -$87.1K – 3335
2024
Q2 		$87.1K Sell
11,519
-39,206
-77% -$396K ﹤0.01% 2647
2024
Q1 		$670K Buy
50,725
+39,310
+344% +$561K ﹤0.01% 2434
2023
Q4 		$118K Buy
+11,415
New +$91K ﹤0.01% 3148
2022
Q3 		– Sell
-651
Closed -$3K – 4626
2022
Q2 		$3K Buy
651
+633
+3,517% +$4.18K ﹤0.01% 4311
2022
Q1 		$0 Buy
+18
New +$155 ﹤0.01% 3706

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KLP
Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Cubist Systematic Strategies's NPCE Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of Neuropace (NPCE) in Q3 2025, closing a stake of 95,618 shares — an estimated $1.07M sold.

Cubist Systematic Strategies first reported a position in NPCE in Q1 2022 and held it in 7 quarters. The position peaked at $1.07M in Q2 2025. 80 funds tracked by Wall St. Rank hold NPCE as of Q3 2025.

  • Cubist Systematic Strategies reported no remaining Neuropace position as of Q3 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 95,618 Neuropace shares in Q3 2025, an estimated $1.07M.
  • Cubist Systematic Strategies first reported a position in Neuropace in Q1 2022 and held it in 7 quarters.
  • Cubist Systematic Strategies's Neuropace position peaked at $1.07M in Q2 2025.
  • 80 funds tracked by Wall St. Rank held Neuropace as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.